531 related articles for article (PubMed ID: 22699418)
1. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
Larson RA; Hochhaus A; Hughes TP; Clark RE; Etienne G; Kim DW; Flinn IW; Kurokawa M; Moiraghi B; Yu R; Blakesley RE; Gallagher NJ; Saglio G; Kantarjian HM
Leukemia; 2012 Oct; 26(10):2197-203. PubMed ID: 22699418
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP
Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220
[TBL] [Abstract][Full Text] [Related]
4. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
[TBL] [Abstract][Full Text] [Related]
5. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;
N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.
Giles FJ; Rosti G; Beris P; Clark RE; le Coutre P; Mahon FX; Steegmann JL; Valent P; Saglio G
Expert Rev Hematol; 2010 Dec; 3(6):665-73. PubMed ID: 21091142
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
Wang J; Shen ZX; Saglio G; Jin J; Huang H; Hu Y; Du X; Li J; Meng F; Zhu H; Hu J; Wang J; Hou M; Hertle S; Menssen HD; Ortmann CE; Tribouley C; Yuan Y; Baccarani M; Huang X
Blood; 2015 Apr; 125(18):2771-8. PubMed ID: 25766724
[TBL] [Abstract][Full Text] [Related]
8. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.
Nakamae H; Fukuda T; Nakaseko C; Kanda Y; Ohmine K; Ono T; Matsumura I; Matsuda A; Aoki M; Ito K; Shibayama H
Int J Hematol; 2018 Mar; 107(3):327-336. PubMed ID: 29076005
[TBL] [Abstract][Full Text] [Related]
10. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Hochhaus A; Saglio G; Hughes TP; Larson RA; Kim DW; Issaragrisil S; le Coutre PD; Etienne G; Dorlhiac-Llacer PE; Clark RE; Flinn IW; Nakamae H; Donohue B; Deng W; Dalal D; Menssen HD; Kantarjian HM
Leukemia; 2016 May; 30(5):1044-54. PubMed ID: 26837842
[TBL] [Abstract][Full Text] [Related]
11. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
Fullmer A; Kantarjian H; Cortes J; Jabbour E
Expert Opin Pharmacother; 2010 Dec; 11(18):3065-72. PubMed ID: 21073351
[TBL] [Abstract][Full Text] [Related]
12. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
13. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
14. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Erba HP; Pham DC; Zaiden R; Vu H; Tai S
Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
17. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
[TBL] [Abstract][Full Text] [Related]
18. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial.
Nakamae H; Yamamoto M; Sakaida E; Kanda Y; Ohmine K; Ono T; Matsumura I; Ishikawa M; Aoki M; Maki A; Shibayama H
Int J Hematol; 2022 Jan; 115(1):33-42. PubMed ID: 34508295
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]